Post- Award Posting of Limited Sources Justification
Awarded Limited / Sole Source Justification Posted
- Solicitation number
- OS316431
- Agency
- Office of the Assistant Secretary for Preparedness and Response Department of Health and Human Services
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 36F79723D0171-75A50323F80027 Federal contract award
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Lexington, Massachusetts 02421, United States
Notice details come from SAM.gov. Updated .
About this opportunity
This Limited/Sole Source Justification Notice from the Department of Health and Human Services approves the acquisition of 250mcg/vial injectable Leukine, a medical countermeasure used to treat neutropenia, from Partner Therapeutics through a sole source contract valued at an unknown amount and spanning September 30, 2023 through September 29, 2026. The justification cites Leukine's unique manufacturing process and risks associated with switching to alternatives as rationale for the noncompetitive award, under which Partner Therapeutics will supply Leukine at $6,000 per vial for the Strategic National Stockpile through December 2023 to align with Project Bioshield and PAHPA directives mandating procurement and storage of specific medical countermeasures.
Notice text
The NAICS code for this procurement is 325412, Pharmaceutical and Medicine Manufacturing. Period of Performance, September 30, 2023 through September 29, 2026, including options and option quantities.
The Administration and strategic Preparedness and Response (ASPR), Division of Strategic National Stockpile (DSNS) awarded a sole source Firm Fixed Price contract to Partner Therapeutics located at 19 Muzzey Street Suite 105, Lexington, MA, 02421-5211
The Division of Strategic National Stockpile (DSNS), under the Administration and Strategic Preparedness and Response (ASPR), granted a sole source Firm Fixed Price contract to Partner Therapeutics. This contract, awarded for the acquisition of GM-CSF Leukine 250MCG/Vial Injectable NDC (71837-5843-05), was facilitated via VA Schedule No. 36F79718D059. It spans a 36-month period and aligns with provisions outlined in the Project BioShield Act of 2004, the Pandemic and All-Hazards Preparedness Act of 2006 (inclusive of subsequent reauthorizations in 2013 and 2019), and the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE). These directives mandate the SNS to procure, store, and dispense specific medical countermeasures, including those mitigating injuries stemming from various exposures such as physical, radiological, and nuclear elements.
Awarded contract 36F79723D0171 to unknown vendor for unknown amount on 2023-09-30.
Attachments
| File | Type | Posted |
|---|---|---|
| ASPR 23-103-S LSJ Leukine Injectables_Approved-Redaction_Redacted.pdf |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity